Literature DB >> 28962857

Mitochondrial cardiomyopathies feature increased uptake and diminished efflux of mitochondrial calcium.

Salah Sommakia1, Patrick R Houlihan2, Sadiki S Deane1, Judith A Simcox3, Natalia S Torres1, Mi-Young Jeong4, Dennis R Winge4, Claudio J Villanueva3, Dipayan Chaudhuri5.   

Abstract

Calcium (Ca2+) influx into the mitochondrial matrix stimulates ATP synthesis. Here, we investigate whether mitochondrial Ca2+ transport pathways are altered in the setting of deficient mitochondrial energy synthesis, as increased matrix Ca2+ may provide a stimulatory boost. We focused on mitochondrial cardiomyopathies, which feature such dysfunction of oxidative phosphorylation. We study a mouse model where the main transcription factor for mitochondrial DNA (transcription factor A, mitochondrial, Tfam) has been disrupted selectively in cardiomyocytes. By the second postnatal week (10-15day old mice), these mice have developed a dilated cardiomyopathy associated with impaired oxidative phosphorylation. We find evidence of increased mitochondrial Ca2+ during this period using imaging, electrophysiology, and biochemistry. The mitochondrial Ca2+ uniporter, the main portal for Ca2+ entry, displays enhanced activity, whereas the mitochondrial sodium-calcium (Na+-Ca2+) exchanger, the main portal for Ca2+ efflux, is inhibited. These changes in activity reflect changes in protein expression of the corresponding transporter subunits. While decreased transcription of Nclx, the gene encoding the Na+-Ca2+ exchanger, explains diminished Na+-Ca2+ exchange, the mechanism for enhanced uniporter expression appears to be post-transcriptional. Notably, such changes allow cardiac mitochondria from Tfam knockout animals to be far more sensitive to Ca2+-induced increases in respiration. In the absence of Ca2+, oxygen consumption declines to less than half of control values in these animals, but rebounds to control levels when incubated with Ca2+. Thus, we demonstrate a phenotype of enhanced mitochondrial Ca2+ in a mitochondrial cardiomyopathy model, and show that such Ca2+ accumulation is capable of rescuing deficits in energy synthesis capacity in vitro.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cardiac metabolism; Mitochondrial calcium uniporter; Mitochondrial sodium-calcium exchanger; OXPHOS deficient cardiomyopathy; Respiratory-chain deficient cardiomyopathy; Whole-mitoplast electrophysiology

Mesh:

Substances:

Year:  2017        PMID: 28962857      PMCID: PMC5652072          DOI: 10.1016/j.yjmcc.2017.09.009

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  68 in total

Review 1.  Cardiac metabolism in heart failure: implications beyond ATP production.

Authors:  Torsten Doenst; Tien Dung Nguyen; E Dale Abel
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 2.  Regulation of mitochondrial ATP synthase in cardiac pathophysiology.

Authors:  Qinqiang Long; Kevin Yang; Qinglin Yang
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

3.  Mitochondrial Ca2+ uniporter and CaMKII in heart.

Authors:  Francesca Fieni; Derrick E Johnson; Andy Hudmon; Yuriy Kirichok
Journal:  Nature       Date:  2014-09-25       Impact factor: 49.962

4.  Reduced activity of mtTFA decreases the transcription in mitochondria isolated from diabetic rat heart.

Authors:  Akio Kanazawa; Yoshihiko Nishio; Atsunori Kashiwagi; Hidetoshi Inagaki; Ryuichi Kikkawa; Kihachiro Horiike
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-04       Impact factor: 4.310

5.  Substrate-binding properties of firefly luciferase. II. ATP-binding site.

Authors:  R T Lee; J L Denburg; W D McElroy
Journal:  Arch Biochem Biophys       Date:  1970-11       Impact factor: 4.013

6.  Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.

Authors:  S Neubauer; M Horn; M Cramer; K Harre; J B Newell; W Peters; T Pabst; G Ertl; D Hahn; J S Ingwall; K Kochsiek
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

7.  Mitochondrial calcium uniporter regulator 1 (MCUR1) regulates the calcium threshold for the mitochondrial permeability transition.

Authors:  Dipayan Chaudhuri; Daniel J Artiga; Sunday A Abiria; David E Clapham
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

8.  Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy.

Authors:  E Arbustini; M Diegoli; R Fasani; M Grasso; P Morbini; N Banchieri; O Bellini; B Dal Bello; A Pilotto; G Magrini; C Campana; P Fortina; A Gavazzi; J Narula; M Viganò
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

9.  Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells.

Authors:  Marco Spinazzi; Alberto Casarin; Vanessa Pertegato; Leonardo Salviati; Corrado Angelini
Journal:  Nat Protoc       Date:  2012-05-31       Impact factor: 13.491

Review 10.  Mitochondrial Cardiomyopathies.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Front Cardiovasc Med       Date:  2016-07-25
View more
  22 in total

1.  MICU1 imparts the mitochondrial uniporter with the ability to discriminate between Ca2+ and Mn2+.

Authors:  Kimberli J Kamer; Yasemin Sancak; Yevgenia Fomina; Joshua D Meisel; Dipayan Chaudhuri; Zenon Grabarek; Vamsi K Mootha
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-06       Impact factor: 11.205

Review 2.  Mitochondrial dysfunction in pathophysiology of heart failure.

Authors:  Bo Zhou; Rong Tian
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

3.  Pyrroloquinoline quinone can prevent chronic heart failure by regulating mitochondrial function.

Authors:  Xuan Xu; Chu Chen; Wen-Jiang Lu; Yi-Ling Su; Jia-Yu Shi; Yu-Chen Liu; Li Wang; Chen-Xi Xiao; Xiang Wu; Qi Lu
Journal:  Cardiovasc Diagn Ther       Date:  2020-06

4.  EFHD1 ablation inhibits cardiac mitoflash activation and protects cardiomyocytes from ischemia.

Authors:  David R Eberhardt; Sandra H Lee; Xue Yin; Anthony M Balynas; Emma C Rekate; Jackie N Kraiss; Marisa J Lang; Maureen A Walsh; Molly E Streiff; Andrea C Corbin; Ying Li; Katsuhiko Funai; Frank B Sachse; Dipayan Chaudhuri
Journal:  J Mol Cell Cardiol       Date:  2022-03-16       Impact factor: 5.763

Review 5.  Mitochondrial Ca2+ signaling.

Authors:  Trayambak Pathak; Mohamed Trebak
Journal:  Pharmacol Ther       Date:  2018-07-20       Impact factor: 12.310

Review 6.  Pharmacological inhibition of the mitochondrial Ca2+ uniporter: Relevance for pathophysiology and human therapy.

Authors:  Katalin Márta; Prottoy Hasan; Macarena Rodríguez-Prados; Melanie Paillard; György Hajnóczky
Journal:  J Mol Cell Cardiol       Date:  2020-10-06       Impact factor: 5.000

Review 7.  Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies.

Authors:  Chrishan J A Ramachandra; Jasper Chua; Shuo Cong; Myu Mai Ja Kp; Winston Shim; Joseph C Wu; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

8.  Mitochondria in Pathological Cardiac Remodeling.

Authors:  Michael P Lazaropoulos; John W Elrod
Journal:  Curr Opin Physiol       Date:  2022-02-19

Review 9.  Mitochondrial calcium exchange in physiology and disease.

Authors:  Joanne F Garbincius; John W Elrod
Journal:  Physiol Rev       Date:  2021-10-26       Impact factor: 37.312

10.  Mitochondrial functional resilience after TFAM ablation in the adult heart.

Authors:  Nasab Ghazal; Jessica N Peoples; Tahmina A Mohiuddin; Jennifer Q Kwong
Journal:  Am J Physiol Cell Physiol       Date:  2021-03-24       Impact factor: 5.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.